One-month DAPT after biodegradable-polymer everolimus-eluting stent implantation in diabetic patients at high-bleeding risk: insights from the POEM trial

Read full text Summarise with VIRAT
Authors: Leon Gramss, Carlo Andrea Pivato, Andrea Pacchioni, Raffaele Piccolo, Carmine Musto, Gennaro Sardella, Ciro Indolfi, Valeria Paradies, Bernhard Reimers, G Condorelli, Luca Testa, Carlo Briguori
+1 more Giulio Giuseppe Stefanini
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Introduction A shortened dual antiplatelet therapy (DAPT) is indicated in patients at a high bleeding risk (HBR) who undergo percutaneous coronary intervention (PCI), but currently limited knowledge exists on the impact of diabetes on clinical outcomes in these patients. Purpose This study aims to evaluate the association between diabetes and clinical outcomes in patients at HBR who underwent PCI with biodegradable-polymer everolimus-eluting stent (BP-EES) and subsequently followed a short 1-month DAPT strategy. Methods The POEM trial enrolled HBR patients undergoing PCI with BP-EES and subsequently treated with 1-month DAPT. In this prespecified subgroup analysis we assessed diabetes-associated outcomes according to the intention-to-treat principle. The primary endpoint was a composite of cardiovascular death, myocardial infarction, or definite/probable stent thrombosis at 1 year. Time-to-event outcomes were analyzed using the Kaplan-Meier method and log-rank test, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox regression models. Results 436 patients were included in the analysis, of whom 166 (38.1%) had diabetes. The primary endpoint occurred in 5.6% in the diabetes group and 4.5% in the non-diabetes group (HR 0.81, 95% CI 0.34-1.91, p=0.62). Similar rates were observed for secondary ischemic endpoints. Bleeding rates were 3.8% and 5.3%, respectively (HR 1.38, 95% CI 0.53-3.59, p=0.51). Conclusions Our analysis demonstrated no significant increase in clinical outcomes associated with diabetes, as well as similar ischemic and bleeding rates as non-diabetic patients. These findings support a short DAPT regimen as a feasible strategy after PCI in diabetic patients with HBR.

Fields of Study & Subjects

Antiplatelet Therapy and Cardiovascular Diseases Coronary Interventions and Diagnostics Acute Myocardial Infarction Research

Publication details

Journal / source
European Heart Journal Supplements
Volume
28
Issue
Supplement_3
Publication date
1 March 2026
Language
EN